There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

New long-acting muscarinic antagonist-long-acting beta agonist users had a decreased risk for a first moderate/severe COPD ...

Dry Powder Inhalers: A Double Win for COPD and Environment By Dennis Thompson HealthDay ReporterTUESDAY, Feb. 24, 2026 (HealthDay News) — Dry powder inhalers might provide a double benefit for people ...

Add Yahoo as a preferred source to see more of our stories on Google. Inhalers that provide fast-acting treatment for people with certain respiratory conditions are contributing to greenhouse gas ...

Please provide your email address to receive an email when new articles are posted on . The single inhaler combined budesonide, glycopyrrolate and formoterol fumarate. The risk for cardiopulmonary ...

Some people with chronic obstructive pulmonary disease (COPD) need to use multiple inhaled medicines each day to control their symptoms. Long-acting combination inhalers that contain more than one ...

A new inhaler that treats chronic obstructive pulmonary disease (COPD) and also helps reduce environmental harm has been approved for use in the UK. This inhaler is already available in India.

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF ...

Telemedicine significantly improved quality of life and inhaler technique in advanced COPD patients compared to traditional follow-up care. The telemedicine group showed a significant reduction in ...

Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...